Aesthetic Gynecology Expectations: Benefits, Limits, Evidence, and How to Decide

Aesthetic gynecology is an umbrella term, not one treatment. It can refer to surgery that changes external tissue, surgery intended to repair or alter the perineum or vaginal canal, energy-based devices, injections, and non-procedural care. The realistic benefit, risk, recovery, and quality of evidence differ sharply between these categories. A useful decision therefore starts with your exact symptom or concern, not with a procedure name.

The central question is simple: what specific change are you hoping for, and is the proposed treatment designed and supported to make that change? Surgery may alter anatomy or reduce a mechanical problem in a suitably assessed person. It cannot guarantee a particular appearance, sensation, level of desire, orgasm, confidence, or relationship outcome. For laser, radiofrequency, and platelet-rich plasma treatments, broad “rejuvenation” claims run ahead of the evidence. This guide explains how to separate plausible goals from promises that current research cannot support.

Key takeaways

• Aesthetic gynecology includes several very different interventions. Evidence about one procedure cannot be transferred automatically to another.
• Female genital cosmetic surgery refers to alteration for appearance when there is no apparent structural or functional abnormality. Treatment for pain, injury, prolapse, incontinence, diagnosed sexual dysfunction, or another clinical condition belongs to a different medical pathway, even if the operation has a similar name (ACOG).
• Vulvas naturally differ in size, shape, colour, symmetry, and proportion. Measurements can describe populations, but they cannot define whether your body is “normal” or whether you need treatment (ACOG, The Journal of Sexual Medicine).
• Labiaplasty studies report high pooled satisfaction, but satisfaction is not proof of clinical effectiveness. Most evidence is observational, outcome measures vary, and individual benefit cannot be predicted from a pooled percentage (2024 systematic review, ACOG).
• As of August 2026, laser and radiofrequency should not be described as proven “vaginal rejuvenation” treatments. A sham-controlled laser trial was negative, professional groups have highlighted insufficient evidence, and Australia’s regulator cancelled all devices listed there for that intended use after finding insufficient evidence for therapeutic use and long-term safety (JAMA, ISSVD and ICS, TGA).
• “No treatment” and “not now” are valid outcomes. A decision can be revisited after symptoms are assessed, postpartum recovery evolves, menopausal symptoms are diagnosed, or outside pressure has been separated from your own preference.

What aesthetic gynecology means

“Aesthetic gynecology” is a broad, non-specific label used for interventions involving the vulva, perineum, vagina, or surrounding tissues. It may include external-tissue surgery such as labiaplasty, internal or perineal surgery, energy-based device treatment, injectable products, or conservative care. These options do not share one purpose, one evidence base, or one recovery.

ACOG uses the more precise term female genital cosmetic surgery for surgical alteration of vulvovaginal anatomy intended for appearance in someone without an apparent structural or functional abnormality. Its definition excludes procedures performed for clinical indications such as pain during intercourse, obstetric or other injury, prolapse, incontinence, reversal of female genital cutting, diagnosed sexual dysfunction, and gender-affirming care (ACOG).

That distinction matters because a treatment name alone does not tell you why it is being considered. Two people may be discussing a similarly named operation for very different reasons. One may have a stable appearance preference. Another may have pain, scarring, pelvic-floor symptoms, tissue injury, or menopausal symptoms that require diagnosis. The assessment, alternatives, evidence, and consent discussion should follow the indication.

“Vaginal rejuvenation” is less helpful as a medical term. The ISSVD and ICS describe the distinction between treatment for atrophy and cosmetic rejuvenation as misleading, while the 2025 AUA/SUFU/AUGS guideline treats genitourinary syndrome of menopause, or GSM, as a defined clinical condition rather than a cosmetic category (ISSVD and ICS, AUA/SUFU/AUGS). If a label seems to cover dryness, laxity, urinary leakage, sexual function, and appearance all at once, pause and ask which diagnosed problem is actually being treated.

Cosmetic preference versus medical indication

A cosmetic preference is not shameful or trivial. You may dislike a feature of your body even when it falls within normal variation. But personal distress does not automatically establish a disease, and a normal anatomical variation does not automatically require correction.

A medical indication starts with a symptom, diagnosis, injury, or functional problem that a clinician can assess. Pain, persistent irritation, a scar after childbirth, urinary or pelvic-floor symptoms, a skin disorder, and menopausal dryness can have different causes and different first-line options. A procedure may be appropriate for one cause and irrelevant to another. This article cannot determine that cause without an individual medical assessment.

ACOG states that procedures performed solely to alter sexual appearance or function, when there is no clinical indication, are not medically indicated and that their safety and effectiveness have not been established. It also advises counselling about possible pain, bleeding, infection, scarring, adhesions, altered sensation, pain during intercourse, and reoperation (ACOG).

The same physical concern can sit in both categories. Appearance may matter to you while tissue also causes discomfort. Mixed motivations are common and do not need to be forced into a moral hierarchy. The practical task is to separate each goal:

• What symptom, if any, needs a diagnosis?
• What appearance preference remains after you understand normal variation?
• Which proposed benefit is anatomical, functional, sexual, emotional, or relational?
• Which part of that goal can the intervention directly affect?
• What alternatives address the parts it cannot affect?

A clear answer may lead to treatment, conservative care, another specialty, time to reflect, or no intervention. All are legitimate outcomes.

Normal vulvar variation

There is no single ideal vulva. Size, shape, pigmentation, surface texture, proportion, and symmetry vary considerably, and these features can change with puberty, ageing, childbirth, and menopause (ACOG). Asymmetry is common, and ACOG notes that there is no consensus definition of labial hypertrophy (ACOG guidance for adolescents).

Recent measurements show why a single “normal size” is misleading. A 2025 study of 247 people aged 17 to 73 who attended gynecology for non-aesthetic reasons found broad variation in labial and clitoral-hood measurements. After adjustment for age and parity, labial length was not significantly associated with concern about genital appearance. The authors warned that reference ranges should be used cautiously to avoid pathologising anatomy outside the measured range (The Journal of Sexual Medicine).

A 2026 systematic review found substantial differences between studies and described its pooled measurements as preliminary and descriptive. Only three studies, including 307 participants, could be combined for the main analysis, and statistical heterogeneity was very high (2026 systematic review). Those numbers are useful for research, not as a ruler for deciding who needs surgery.

Images are also unreliable standards. Angles, positioning, hair removal, lighting, selection, editing, and the limited range of bodies shown online can create an artificial visual norm. A small qualitative study of 14 labiaplasty patients identified media influence, negative commentary, physical and appearance concerns, and sexual wellbeing among the themes shaping requests. Its small Australian sample cannot tell us how common each motive is, but it illustrates why context deserves discussion (Aesthetic Surgery Journal).

Normal variation does not mean symptoms should be dismissed. Persistent pain, itching, skin change, bleeding, discharge, urinary symptoms, a new lump, or discomfort during activity deserves assessment. Reassurance about anatomy and investigation of symptoms can happen together.

Why people consider treatment

People arrive at this question through many routes. There is no single “type” of patient, and motivations often overlap.

Physical comfort. A person may report rubbing, pinching, pulling, irritation, discomfort with clothing or exercise, pain during intimacy, or symptoms after childbirth. These descriptions do not prove which tissue is responsible, but they give a clinician a concrete problem to investigate.

Appearance. Someone may have a stable preference about contour, symmetry, prominence, or age-related change. The preference can be genuinely their own. It can also be shaped by a narrow set of images, past comments, hair-removal practices, or a partner’s reaction. ACOG has identified exposure to idealised genital images and awareness of cosmetic genital surgery among proposed drivers of demand (ACOG guidance for adolescents).

After pregnancy or birth. Tissue healing, pelvic-floor function, scars, hormonal changes, feeding status, future pregnancy plans, sleep, and caregiving demands can all affect what a person notices and what recovery from another procedure would involve. The authoritative sources cited here do not set a universal postpartum waiting period. Timing should be individualised rather than reduced to a fixed month count.

Menopause-related symptoms. Dryness, burning, pain during sex, and urinary symptoms may fit GSM, a clinical syndrome that needs its own assessment and treatment pathway. Calling these concerns “ageing” or “rejuvenation” can obscure a treatable medical condition (AUA/SUFU/AUGS).

Sexual, emotional, or relationship hopes. Pain relief could remove one barrier to intimacy, but desire, arousal, orgasm, body image, mood, relationship safety, communication, hormones, medication effects, and neurological factors do not reduce to anatomy. ACOG states that current evidence does not support improvement in body image, libido, or sexual satisfaction as established outcomes of female genital cosmetic surgery (ACOG).

Outside influence. A partner, family member, friend, clinician, or social-media feed may have introduced the idea. The AUGS patient factsheet advises that the decision belongs to the patient and should be made without outside pressure (AUGS and Voices for PFD). A useful test is not whether others approve. It is whether the wish remains when their comments are mentally removed.

Procedure categories compared

The purpose of this comparison is orientation, not treatment selection. Exact techniques, eligibility, preparation, recovery, and complication rates belong in procedure-specific counselling.

One treatment category should not be used as shorthand for another. A study of labiaplasty cannot establish that a laser improves GSM. A report about sexual-function scores after surgery cannot prove that surgery increases desire for an individual. A device’s ability to heat or ablate tissue does not prove the marketed clinical outcome.

Realistic benefits and hard limits

A realistic expectation is specific enough to observe. “Less pulling during cycling” is testable. “A smaller visible contour in fitted clothing” is testable. “Repair this identified scar” is testable. By contrast, “feel whole again,” “restore my marriage,” “look perfect,” or “become more desirable” places the burden of a broad life outcome on a local intervention.

Possible benefits depend on the intervention and indication. They may include a defined anatomical change, relief of a mechanical symptom, repair of diagnosed tissue injury, or treatment of a separately diagnosed condition. None can be promised in advance. The AUGS patient factsheet states plainly that all surgery carries risk and results are not guaranteed (AUGS and Voices for PFD).

Hard limits deserve equal space:

• No procedure can promise an exact visual match to a photograph.
• Symmetry can be a goal, but natural and postoperative asymmetry may remain.
• Sensation may change. Preservation or enhancement cannot be guaranteed.
• Relief of pain caused by one mechanical factor does not treat every possible cause of painful sex.
• A procedure does not reliably create desire, arousal, orgasm, confidence, or relationship security.
• A short-term change does not prove a durable benefit.
• A high group satisfaction percentage does not predict your personal result.
• A “non-surgical” label does not mean risk-free or evidence-based.

These limits are not arguments for or against treatment. They define what informed consent should contain. A reasonable plan connects one intervention to one or more specific goals and explains what will remain unchanged.

What labiaplasty satisfaction evidence means

Labiaplasty has the largest satisfaction literature within this umbrella category, but the numbers need careful interpretation. A 2024 systematic review pooled 53 studies with usable satisfaction data and 3,766 observations. It reported 94.43% satisfaction, with a 95% confidence interval of 93.16% to 95.48% (2024 systematic review). A separate review of 43 studies and 3,804 patients reported 99% pooled satisfaction, with a 95% confidence interval of 97% to 99%, but heterogeneity was higher (2021 systematic review).

Those pooled figures are not an all-purpose “satisfaction rate.” The reviews differ in included studies, methods, techniques, outcome definitions, and complication estimates. Most underlying evidence is observational. People who choose surgery, are accepted for it, return for follow-up, and answer a survey may differ from those who do not. Provider-collected outcomes may miss experiences captured through independent patient reporting.

Uncontrolled before-and-after studies are vulnerable to expectancy effects, regression to the mean, natural recovery, and other changes over time. The 2025 meta-analysis called the certainty low, found no clear superiority of one technique, and highlighted the need for longer follow-up (2025 FGCS review).

For readers who want to review source-led material, the established aesthetic gynecology research library is the appropriate route. This umbrella guide intentionally does not reproduce technique comparisons, detailed anatomy, or complication-rate tables.

Risks and recovery variability

Risks vary with the procedure, technique, health history, anatomy, setting, anaesthesia, combined treatments, and aftercare. For genital cosmetic surgery, ACOG lists pain, bleeding, infection, scarring, adhesions, altered sensation, painful intercourse, and reoperation among the issues that should be discussed before consent (ACOG). Energy-based devices and injections have different risk profiles and should not be described by a surgical complication list alone.

Even within labiaplasty, published complication estimates differ materially between systematic reviews. One 2024 review reported an 8.88% pooled total complication estimate, while an earlier review produced lower estimates for some individual complications. Definitions, reporting methods, techniques, and study selection differ, so a single number can create false precision (2024 review, 2021 review).

Recovery cannot be safely summarised as one universal week-by-week schedule. External surgery, perineal repair, vaginal surgery, device treatment, and injections do not share the same healing process. Swelling, wound care, pain control, activity limits, work demands, exercise, intimacy, travel, and follow-up all depend on what was done and how you are healing.

Before agreeing to any procedure, you should receive instructions tailored to that intervention and to your circumstances. Your own clinician’s written advice should govern activity and follow-up. Do not use another patient’s timeline, a social-media post, or a generic article to clear yourself for exercise or sex.

For procedure-specific information, use the relevant treating team’s written plan. If travel is involved, continuity and emergency planning matter because complications and revisions can add medical and financial burden (CDC Yellow Book).

Psychological screening and BDD

Body dysmorphic disorder, or BDD, is a mental health condition. Screening for it is not a judgement about vanity, intelligence, or whether a concern feels real. It is also not a diagnosis made from a checklist in an article.

A 2024 meta-analysis across cosmetic and reconstructive settings estimated a pooled BDD prevalence of 18.6% among people presenting for procedures. The studies covered different specialties and populations, and heterogeneity was extremely high, so that number should not be treated as the prevalence in aesthetic gynecology or used to label an individual (2024 meta-analysis).

ACOG advises that clinicians have enough training to recognise possible sexual-function, depression, anxiety, and other psychiatric concerns; assessment for BDD should occur when indicated, with referral before surgery when psychological concerns are suspected (ACOG). Screening is a safety step because the right support may be psychological, procedural, both, or neither at that moment.

Consider pausing for professional support if the concern occupies much of your day, checking or comparison feels hard to control, reassurance never lasts, you believe one precise physical change must solve broad distress, or the decision is tied to severe anxiety, depression, or a crisis. These experiences do not mean your concern is imaginary. They mean a broader assessment could protect you from asking a procedure to carry more than it can.

If you are in immediate danger or thinking about harming yourself, seek emergency help now through local emergency services or the nearest emergency department. Do not wait for a cosmetic consultation.

Laser, radiofrequency, and PRP evidence

As of August 2026, laser, radiofrequency, and PRP should be discussed as separate technologies with separate indications. They should not be bundled under a promise of “rejuvenation.”

Laser

The strongest sham-controlled evidence is not reassuring. In a double-blind randomised trial of 85 postmenopausal women, fractional carbon dioxide laser did not improve symptom severity, quality of life, or vaginal histology compared with sham treatment at 12 months (JAMA). This trial addressed postmenopausal vaginal symptoms, not every device or proposed use, but it shows why uncontrolled improvement cannot be assumed to prove efficacy.

The 2018 ISSVD/ICS statement recommended against laser and radiofrequency for lichen sclerosus, vulvodynia, urinary incontinence, vulvovaginal atrophy, or “rejuvenation” outside properly designed clinical trials (ISSVD and ICS). An FDA compliance letter that year also said it could not identify clearance or approval supporting a manufacturer’s marketed menopause and intimacy claims for a named laser device (FDA compliance letter). Device clearance for cutting or ablation is not the same as proof for a rejuvenation claim.

The regulatory picture is jurisdiction-specific and continues to change. Australia’s Therapeutic Goods Administration reported in August 2026 that its post-market review found insufficient clinical evidence to support therapeutic use and long-term safety for devices intended for vaginal rejuvenation. It confirmed that all such devices had been cancelled from the Australian Register of Therapeutic Goods and that none were approved there for that intended use (TGA). That Australian action is not a Saudi approval decision, but it is highly relevant to claims about the maturity of the evidence.

Radiofrequency

The European Society for Sexual Medicine concluded that radiofrequency vaginal treatments had not been studied thoroughly enough for decisive safety or efficacy recommendations. It found insufficient evidence for GSM and no basis for a recommendation for vaginal laxity, which itself lacks a uniform definition (The Journal of Sexual Medicine).

A 2024 systematic review found improvements in sexual-function scores in observational laser and radiofrequency studies, but the vaginal-laxity questionnaire did not improve significantly versus sham. Nearly all non-randomised studies were at serious risk of bias (2024 systematic review). The appropriate conclusion is uncertainty, not proof of tightening or sexual benefit.

PRP

PRP uses a person’s own platelet-rich plasma, but biological plausibility does not establish clinical benefit. A 2026 systematic review included 18 studies and 480 patients, only two of which were randomised trials. The authors said benefits may exist, yet the wide variation in protocols, small samples, and methodological limitations prevented definitive conclusions (2026 PRP systematic review).

For any device or injection, ask for the exact product, intended indication, regulatory status in the country of treatment, comparison treatment, expected magnitude and duration of benefit, known harms, alternatives, and what happens if it does not work. A testimonial or package name cannot answer those questions.

Postpartum concerns and GSM

Postpartum concerns and GSM are different clinical contexts. They can produce overlapping words such as “dryness,” “looseness,” “discomfort,” or “change,” but those words do not establish the same cause.

After childbirth, symptoms may relate to healing tissue, scars, pelvic-floor muscle function, nerve effects, hormones, breastfeeding, prolapse, urinary problems, pain conditions, or normal anatomical change. Future pregnancy plans and the practical ability to recover also matter. The authoritative sources cited here do not support a universal fixed waiting period. Timing should follow individual healing, diagnosis, family plans, health, and the proposed treatment. Cleveland Clinic notes directionally that pregnancy and birth may stretch the labia and that some people may prefer to wait until they have finished adding to their family, but it does not set a fixed interval (Cleveland Clinic).

GSM is associated with menopause and other low-oestrogen states and can involve genital, sexual, and urinary symptoms. The 2025 AUA/SUFU/AUGS guideline treats GSM as a clinical condition and notes that examination findings do not necessarily correlate with symptom severity (AUA/SUFU/AUGS). A person with dryness or pain needs a symptom-led evaluation rather than an assumption that tissue requires “rejuvenation.”

For a fuller distinction, read Vaginal Changes in Menopause: Laxity, Dryness and GSM Explained. When the diagnosis is not established, the established dryness and laxity assessment page is a more appropriate route than choosing a device or operation in advance.

Your rights in Saudi Arabia

For residents of Saudi Arabia and people travelling to Riyadh for care, consent is more than a signature. In March 2026, the Saudi Ministry of Health stated that patients should not undergo a medical procedure before giving written informed consent that clearly explains the details needed for decision-making. Patients are entitled to keep a copy of the consent form, receive initial cost information for non-emergency services before treatment, obtain a stamped information card for materials used, and review the practitioner’s licence and academic qualifications. The Ministry directs reports of violations to its 937 contact centre (Saudi Ministry of Health).

These rights are practical. Before you consent:

1. Read the document in a language you understand and ask for clarification.
2. Check that the procedure, intended benefit, material risks, alternatives, and option of no treatment match the conversation.
3. Keep your copy of the consent form and any product information card that applies.
4. Confirm the initial cost and ask what follow-up or management of complications may cost.
5. Exercise your right to review the practitioner’s licence and academic qualifications.

The Ministry’s May 2026 enforcement update urged the public to verify facility licensing and practitioner classification before receiving services. It reported violations including unlicensed practice, exceeding approved clinical privileges, and infection-control deficiencies (Saudi Ministry of Health). Detailed credential and facility verification belongs in a separate provider-selection process, not in an expectations guide.

Personal expectations worksheet

Use this worksheet before deciding on a procedure name. Write the answers privately, then take them into a clinical discussion.

1. Describe the concern without diagnosing yourself

• What exactly do I notice?
• Is it pain, irritation, pulling, dryness, urinary change, a scar, appearance, or a mixture?
• When does it happen, and what activities make it better or worse?
• Has it changed recently?

2. Separate symptom from appearance

Complete both sentences, even if one answer is “none”:

• The physical symptom I want assessed is:
• The appearance change I would prefer is:

This separation prevents a cosmetic label from obscuring a medical cause, and it prevents a symptom from being used automatically to justify an unrelated procedure.

3. Name one observable benefit

Finish this sentence: I would consider treatment beneficial if, after appropriate healing, this specific thing changed:

Choose something concrete. “Less discomfort in a named activity” or “a defined contour change” is easier to evaluate than “feel normal” or “feel desirable.”

4. State the hard limits

Finish these sentences:

• This treatment is not expected to change:
• I understand it cannot guarantee:
• If the result is improved but not exact or symmetrical, I would feel:

5. Test the source of the decision

• Would I still want assessment if nobody else had commented?
• Am I comparing myself with a narrow or edited visual standard?
• Is someone pressuring me, directly or indirectly?
• Am I making this decision during an acute life transition?
• Would more time or a second kind of support change my answer?

The AUGS patient factsheet emphasises that the decision should be yours, without pressure from friends, family, a partner, a doctor, or social media (AUGS and Voices for PFD).

6. Define your evidence threshold

• What evidence supports the exact intervention for my exact goal?
• Is that evidence randomised, observational, or based mainly on testimonials?
• How long were people followed?
• What remains uncertain?
• Would I accept the intervention if the likely benefit is smaller or less durable than I hope?

7. Define unacceptable trade-offs

• Which risks would make the expected benefit not worth it for me?
• How much uncertainty can I accept?
• Can I manage the required recovery, privacy, caregiving, work, and follow-up?
• What is my plan if the result disappoints me or a complication occurs?

8. Decide among four valid next steps

After completing the worksheet, your next step may be:

• medical assessment of a symptom;
• more information and time;
• discussion of procedural and non-procedural options;
• no treatment.

The worksheet does not determine eligibility. Its job is to turn a vague hope into questions that can be examined honestly.

The next step

Once you understand the expected benefit, limits, evidence, and personal trade-offs, the adjacent decision is how to evaluate the person, facility, consent process, and follow-up plan. Keep that provider-selection step separate from the outcome evidence so neither substitutes for the other.

If you want to read further now, the established labiaplasty service page provides a procedure-specific route, while the research library provides wider source-led material. A clinical discussion at Dr. Dina Rezk Clinic in Riyadh, Saudi Arabia, should begin with your symptoms, goals, and questions. It should not be treated as a promise that a procedure is suitable or will produce a particular result.

Frequently asked questions

Conclusion

A good aesthetic gynecology decision is not built around the most persuasive procedure name. It begins with a specific concern, a diagnosis where symptoms are present, an understanding of normal variation, and an honest link between the proposed intervention and the change you want.

The evidence is not equally strong across this field. Published labiaplasty cohorts report high satisfaction, but those figures do not prove clinical effectiveness or predict an individual result. Sexual-function findings are uncertain. Laser, radiofrequency, and PRP do not support broad promises of rejuvenation. Recovery and risk vary too much for one universal timeline.

Use the worksheet to make your goal observable and to name what treatment cannot change. Exercise your consent and information rights in Saudi Arabia. If you proceed to a consultation, carry the same expectations into the next decision: checking the provider, facility, evidence, consent process, and aftercare plan. And if the most accurate answer is “not now” or “no treatment,” that is still a medically and personally valid decision.

References

1. American College of Obstetricians and Gynecologists. Elective Female Genital Cosmetic Surgery. Committee Opinion No. 795.
2. American College of Obstetricians and Gynecologists. Breast and Labial Surgery in Adolescents.
3. Comprehensive Assessment of Labiaplasty Techniques and Tools, Satisfaction Rates, and Risk Factors. Systematic review and meta-analysis. Aesthetic Surgery Journal. 2024.
4. Aesthetic Labiaplasty: A Systematic Review and Meta-analysis. 2021.
5. Systematic review of outcomes and outcome-measurement heterogeneity in cosmetic gynecology. International Urogynecology Journal. 2020.
6. Patient-reported outcome measures in female genital cosmetic surgery. Aesthetic Surgery Journal. 2020.
7. Female sexual function after female genital cosmetic surgery. Systematic review and meta-analysis. 2025.
8. Female sexual function after labiaplasty. Systematic review and meta-analysis. 2025.
9. Labia minora measurements. Systematic review and meta-analysis. 2026.
10. Vulvar nomograms and genital self-image. The Journal of Sexual Medicine. 2025.
11. Body dysmorphic disorder prevalence in aesthetic and reconstructive surgery. Systematic review and meta-analysis. 2024.
12. Effect of fractional carbon dioxide laser versus sham treatment on postmenopausal vaginal symptoms. JAMA. 2021.
13. International Society for the Study of Vulvovaginal Disease and International Continence Society. Joint statement on laser and radiofrequency. 2018.
14. Therapeutic Goods Administration. Post-market review of energy-based devices used for vaginal rejuvenation. Updated August 2026.
15. Energy-based treatments and vaginal laxity. Systematic review and meta-analysis. 2024.
16. Platelet-rich plasma in vulvovaginal disorders. Systematic review. 2026.
17. American Urological Association, SUFU, and AUGS. Genitourinary Syndrome of Menopause Guideline. 2025.
18. Saudi Ministry of Health. Patient rights and safety requirements in cosmetic clinics. 2026.
19. Saudi Ministry of Health. Inspection campaign and enforcement update. 2026.
20. AUGS and Voices for PFD. Cosmetic Gynecology Patient Factsheet. © 2024.